Mirikizumab Shows Continued Symptom Improvement and Reduction of Intestinal Inflammation in Patients with Crohn ' s Disease in 52-Week Phase 2 Trial

INDIANAPOLIS, Oct. 12, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) announced today new efficacy and safety data from the Phase 2 SERENITY study evaluating mirikizumab in patients with moderately to severely active Crohn ' s...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials